ClinicalTrials.Veeva

Menu
E

El Paso Pulmonary Association | West El Paso, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Verekitug
UPB-101
Lunsekimig
Buloxibutid
BLU-5937
AP01
Bexotegrast
LTI-03
BI 1291583
PLN-74809

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 12 total trials

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT st...

Active, not recruiting
Severe Asthma
Drug: Verekitug
Drug: Placebo

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmona...

Enrolling
Idiopathic Pulmonary Fibrosis (IPF)
Device: Dry Powder Inhaler
Drug: Placebo

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Pulmonary Fibrosis Secondary to Systemic Sclerosis
Pulmonary Fibrosis
Drug: AP01
Other: Placebo

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pul...

Enrolling
Chronic Obstructive Pulmonary Disease
Other: Placebo
Drug: Verekitug

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and phar...

Active, not recruiting
Idiopathic Pulmonary Fibrosis (IPF)
Drug: Placebo
Drug: Buloxibutid

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimi...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Lunsekimig
Drug: Placebo

The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symp...

Active, not recruiting
COPD
Smoking
Other: Cigarette
Other: THS
Locations recently updated

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and...

Enrolling
Bronchiectasis
Drug: Placebo matching BI 1291583
Drug: BI 1291583

Trial sponsors

U
A
B
Boehringer Ingelheim logo
K
P
P
Sanofi logo
V
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems